CD38 and Recurrent upper respiratory tract infections: Data from a number of randomized clinical trials also found the addition of Dara to PIs/immunomodulatory drugs increases the risk of infection (upper respiratory tract infection: from 14% to 44% and 23% to 63%),9, 10, 11, 25, 47 which might be attributable to the immunoparesis induced by the CD38 receptor downregulation and the depletion of CD38‐expressing immune cells.48